Opioids in cancer: The κ‑opioid receptor (Review)
- Authors:
- Qier Zhou
- Zhiwei Zhang
- Songkai Long
- Wanjun Li
- Baiyun Wang
- Na Liang
-
Affiliations: Department of Anesthesiology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China, Key Laboratory of Cancer Cellular and Molecular Pathology, Cancer Research Institute of Hengyang Medical College, University of South China, Hengyang, Hunan 421001, P.R. China - Published online on: December 8, 2021 https://doi.org/10.3892/mmr.2021.12560
- Article Number: 44
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. April 5–2021.(Epub ahead of print). View Article : Google Scholar | |
|
Rogers TJ: Kappa opioid receptor expression and function in cells of the immune system. Handb Exp Pharmacol. 271:419–433. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Trescot AM: Review of the role of opioids in cancer pain. J Natl Compr Cancer Netw. 8:1087–1094. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lohse I and Brothers SP: Pathogenesis and treatment of pancreatic cancer related pain. Anticancer Res. 40:1789–1796. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mercadante S and Vitrano V: Pain in patients with lung cancer: Pathophysiology and treatment. Lung Cancer. 68:10–15. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Szczepaniak A, Fichna J and Zielińska M: Opioids in cancer development, progression and metastasis: Focus on colorectal cancer. Curr Treat Options Oncol. 21:62020. View Article : Google Scholar : PubMed/NCBI | |
|
Satija A, Ahmed SM, Gupta R, Ahmed A, Rana SPS, Singh SP, Mishra S and Bhatnagar S: Breast cancer pain management-a review of current & novel therapies. Indian J Med Res. 139:216–225. 2014.PubMed/NCBI | |
|
Ing JW: Head and neck cancer pain. Otolaryngol Clin North Am. 50:793–806. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Zhang H, Weng ML, Zhang J, Jiang N, Cata JP, Ma D, Chen WK and Miao CH: Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J Cell Physiol. 236:4445–4454. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Y, Ren Z, Ma S, Yan W, He M, Wang D and Ding P: Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. Ren Fail. 39:258–264. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ustun F, Durmus-Altun G, Altaner S, Tuncbilek N, Uzal C and Berkarda S: Evaluation of morphine effect on tumour angiogenesis in mouse breast tumour model, EATC. Med Oncol. 28:1264–1272. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guerrero Orriach JL, Raigon Ponferrada A, Malo Manso A, Herrera Imbroda B, Escalona Belmonte JJ, Ramirez Aliaga M, Ramirez Fernandez A, Crespo JD, Soriano Perez AM, Fontaneda Heredia A, et al: Anesthesia in combination with propofol increases disease-free survival in bladder cancer patients who undergo radical tumor cystectomy as compared to inhalational anesthetics and opiate-based analgesia. Oncology. 98:161–167. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, Uchida M, Maeno K, Fukuda S, Nishie H, et al: Opioid dose and survival of patients with incurable nonsmall cell lung cancer: A prospective cohort study. J Palliat Med. 21:1436–1441. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gong S, Ying L, Fan Y and Sun Z: Fentanyl inhibits lung cancer viability and invasion via upregulation of miR-331-3p and repression of HDAC5. Onco Targets Ther. 13:13131–13141. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Qin Y, Zhong Y, Qin Y, Wei Y, Li L and Xie Y: Fentanyl inhibits the progression of gastric cancer through the suppression of MMP-9 via the PI3K/Akt signaling pathway. Ann Transl Med. 8:1182020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang XL, Chen ML and Zhou SL: Fentanyl inhibits proliferation and invasion of colorectal cancer via β-catenin. Int J Clin Exp Pathol. 8:227–235. 2015.PubMed/NCBI | |
|
Sasamura T, Nakamura S, Iida Y, Fujii H, Murata J, Saiki I, Nojima H and Kuraishi Y: Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 441:185–191. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fichna J and Janecka A: Opioid peptides in cancer. Cancer Metastasis Rev. 23:351–366. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chatikhine VA, Chevrier A, Chauzy C, Duval C, d'Anjou J, Girard N and Delpech B: Expression of opioid peptides in cells and stroma of human breast cancer and adenofibromas. Cancer Lett. 77:51–56. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Zagon IS, Hytrek SD and McLaughlin PJ: Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol. 271:R511–R518. 1996.PubMed/NCBI | |
|
Hatzoglou A, Gravanis A, Margioris AN, Zoumakis E and Castanas E: Identification and characterization of opioid-binding sites present in the Ishikawa human endometrial adenocarcinoma cell line. J Clin Endocrinol Metab. 80:418–423. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Roth KA and Barchas JD: Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer. 57:769–773. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Singleton PA, Mirzapoiazova T, Hasina R, Salgia R and Moss J: Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 113 (Suppl 1):i103–i108. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J and Singleton PA: Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 116:857–867. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R and Kleijnen J: Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 28:833–845. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cieślińska A, Sienkiewicz-Szłapka E, Kostyra E, Fiedorowicz E, Snarska J, Wroński K, Tenderenda M, Jarmołowska B and Matysiewicz M: µ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer. Tumour Biol. 36:4655–4660. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Singleton PA, Moss J, Karp DD, Atkins JT and Janku F: The mu opioid receptor: A new target for cancer therapy? Cancer. 121:2681–2688. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Steele GL, Dudek AZ, Gilmore GE, Richter SA, Olson DA, Eklund JP and Zylla DM: Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am J Clin Oncol. 43:591–597. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Ham S, Hong H, Moon C and Im HI: Brain reward circuits in morphine addiction. Mol Cells. 39:645–653. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE and Vallejo R: Opioid complications and side effects. Pain Physician. 11 (Suppl 2):S105–S120. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bodnar RJ: Endogenous opioid modulation of food intake and body weight: Implications for opioid influences upon motivation and addiction. Peptides. 116:42–62. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bagley EE and Ingram SL: Endogenous opioid peptides in the descending pain modulatory circuit. Neuropharmacology. 173:1081312020. View Article : Google Scholar : PubMed/NCBI | |
|
Barron BA: Opioid peptides and the heart. Cardiovasc Res. 43:13–16. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Gein SV and Baeva TA: Endogenous opioid peptides in regulation of innate immunity cell functions. Biochemistry (Mosc). 76:309–319. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mercadante S and Romualdi P: The therapeutic potential of novel kappa opioid receptor-based treatments. Curr Med Chem. 27:2012–2020. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Waldhoer M, Bartlett SE and Whistler JL: Opioid receptors. Annu Rev Biochem. 73:953–990. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Minami M, Toya T, Katao Y, Maekawa K, Nakamura S, Onogi T, Kaneko S and Satoh M: Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett. 329:291–295. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Schoffelmeer AN, Hogenboom F and Mulder AH: Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br J Pharmacol. 122:520–524. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Brooks AI, Standifer KM, Rossi GC, Mathis JP and Pasternak GW: Characterizing kappa3 opioid receptors with a selective monoclonal antibody. Synapse. 22:247–252. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Cahill CM, Taylor AM, Cook C, Ong E, Morón JA and Evans CJ: Does the kappa opioid receptor system contribute to pain aversion? Front Pharmacol. 5:2532014. View Article : Google Scholar : PubMed/NCBI | |
|
Crowley NA and Kash TL: Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 62:51–60. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan X, Mancuso KF and Kaye AD: Revisiting oxycodone analgesia: A review and hypothesis. Anesthesiol Clin. 35:e163–e174. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N and Hilgart JS: Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 8:Cd0038702017.PubMed/NCBI | |
|
Jin WQ, Tai KK, Chan TK and Wong TM: Further characterization of [3H]U69593 binding sites in the rat heart. J Mol Cell Cardiol. 27:1507–1511. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Simonin F, Gavériaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattéi MG, Charron G, Bloch B and Kieffer B: kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA. 92:7006–7010. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Gavériaux-Ruff C, Peluso J, Befort K, Simonin F, Zilliox C and Kieffer BL: Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors. Brain Res Mol Brain Res. 48:298–304. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YJ, Rasakham K, Huang P, Chudnovskaya D, Cowan A and Liu-Chen LY: Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5′-O-(3-[35S]thiotriphosphate) binding in the guinea pig. J Pharmacol Exp Ther. 339:438–450. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Machelska H and Celik M: Opioid receptors in immune and glial cells-implications for pain control. Front Immunol. 11:3002020. View Article : Google Scholar : PubMed/NCBI | |
|
Spasov AA, Grechko O and Shtareva DM: Kappa-opioid receptor: Molecular structure and function. Eksp klin Farmakol. 77:27–35. 2014.(In Russian). | |
|
Carroll FI and Carlezon WA Jr: Development of κ opioid receptor antagonists. J Med Chem. 56:2178–2195. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamizu K, Hamada Y and Narita M: κ Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol. 172:268–276. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Luo J, Tian J, Zou Q and Wang X: The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer. Med Hypotheses. 150:1105682021. View Article : Google Scholar : PubMed/NCBI | |
|
Wigmore T and Farquhar-Smith P: Opioids and cancer: Friend or foe? Curr Opin Support Palliat Care. 10:109–118. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Strang P: Cancer pain-a provoker of emotional, social and existential distress. Acta Oncol. 37:641–644. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Reiche EM, Nunes SO and Morimoto HK: Stress, depression, the immune system, and cancer. Lancet Oncol. 5:617–625. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Edwards KA, Havelin JJ, McIntosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW and Streicher JM: A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain. J Pain. 19:612–625. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YF, Xu QX, Liao LD, Xu XE, Wu JY, Shen J, Wu ZY, Shen JH, Li EM and Xu LY: κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum Pathol. 44:1756–1765. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Diao CT, Li L, Lau SY, Wong TM and Wong NS: kappa-Opioid receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 human epithelial tumor cell line. Biochim Biophys Acta. 1499:49–62. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Ma Z and Lei Y: The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro. BMC Anesthesiol. 21:2102021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q and Zeng W: Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer. 17:5532017. View Article : Google Scholar : PubMed/NCBI | |
|
Tripolt S, Neubauer HA, Knab VM, Elmer DP, Aberger F, Moriggl R and Fux DA: Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. Neoplasia. 23:270–279. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Brejchova J, Holan V and Svoboda P: Expression of opioid receptors in cells of the immune system. Int J Mol Sci. 22:3152020. View Article : Google Scholar : PubMed/NCBI | |
|
Pert CB and Snyder SH: Opiate receptor: Demonstration in nervous tissue. Science. 179:1011–1014. 1973. View Article : Google Scholar : PubMed/NCBI | |
|
Kiguchi N, Ding H, Kishioka S and Ko MC: Nociceptin/orphanin FQ peptide receptor-related ligands as novel analgesics. Curr Top Med Chem. 20:2878–2888. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dhaliwal A and Gupta M: Physiology, opioid receptor. StatPearls (Internet). StatPearls Publishing; Treasure Island, FL: 2021 | |
|
Valentino RJ and Volkow ND: Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 43:2514–2520. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chavkin C, James IF and Goldstein A: Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 215:413–415. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Bruchas MR, Land BB and Chavkin C: The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 1314:44–55. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Terenius L: From opiate pharmacology to opioid peptide physiology. Ups J Med Sci. 105:1–15. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Goldstein A and Naidu A: Multiple opioid receptors: Ligand selectivity profiles and binding site signatures. Mol Pharmacol. 36:265–272. 1989.PubMed/NCBI | |
|
Giros B, Pohl M, Rochelle JM and Seldin MF: Chromosomal localization of opioid peptide and receptor genes in the mouse. Life Sci. 56:PL369–PL375. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Wei LN and Loh HH: Transcriptional and epigenetic regulation of opioid receptor genes: Present and future. Annu Rev Pharmacol Toxicol. 51:75–97. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xie GX, Meng F, Mansour A, Thompson RC, Hoversten MT, Goldstein A, Watson SJ and Akil H: Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc Natl Acad Sci USA. 91:3779–3783. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, et al: Structure of the human κ-opioid receptor in complex with JDTic. Nature. 485:327–332. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Akil H and Watson SJ: Cloning of kappa opioid receptors: Functional significance and future directions. Prog Brain Res. 100:81–86. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Law PY, Loh HH and Wei LN: Insights into the receptor transcription and signaling: Implications in opioid tolerance and dependence. Neuropharmacology. 47 (Suppl 1):S300–S311. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Hasani R and Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 115:1363–1381. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bruchas MR, Xu M and Chavkin C: Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport. 19:1417–1422. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kam AY, Chan AS and Wong YH: Kappa-opioid receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells. J Pharmacol Exp Ther. 310:301–310. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Finley MJ, Steele A, Cornwell WD and Rogers TJ: Transcriptional regulation of the major HIV-1 coreceptor, CXCR4, by the kappa opioid receptor. J Leukoc Biol. 90:111–121. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Georgoussi Z, Georganta EM and Milligan G: The other side of opioid receptor signalling: Regulation by protein-protein interaction. Curr Drug Targets. 13:80–102. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fink RM and Gallagher E: Cancer pain assessment and measurement. Semin Oncol Nurs. 35:229–234. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wiffen PJ, Cooper TE, Anderson AK, Gray AL, Grégoire MC, Ljungman G and Zernikow B: Opioids for cancer-related pain in children and adolescents. Cochrane Database Syst Rev. 7:Cd0125642017.PubMed/NCBI | |
|
Wiffen PJ, Wee B, Derry S, Bell RF and Moore RA: Opioids for cancer pain-an overview of cochrane reviews. Cochrane Database Syst Rev. 7:Cd0125922017.PubMed/NCBI | |
|
Paton KF, Atigari DV, Kaska S, Prisinzano T and Kivell BM: Strategies for developing κ opioid receptor agonists for the treatment of pain with fewer side effects. J Pharmacol Exp Ther. 375:332–348. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Escobar ADP, Casanova JP, Andrés ME and Fuentealba JA: Crosstalk between kappa opioid and dopamine systems in compulsive behaviors. Front Pharmacol. 11:572020. View Article : Google Scholar : PubMed/NCBI | |
|
McLaughlin JP, Li S, Valdez J, Chavkin TA and Chavkin C: Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology. 31:1241–1248. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Knoll AT and Carlezon WA Jr: Dynorphin, stress, and depression. Brain Res. 1314:56–73. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Carlezon WA Jr and Krystal AD: Kappa-Opioid antagonists for psychiatric disorders: From bench to clinical trials. Depress Anxiety. 33:895–906. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Falcon E, Maier K, Robinson SA, Hill-Smith TE and Lucki I: Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl). 232:907–915. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmadi J, Jahromi MS and Ehsaei Z: The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: A randomized, double-blind, clinical trial. Trials. 19:4622018. View Article : Google Scholar : PubMed/NCBI | |
|
Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, Nasrallah H and Amore M: The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: A systematic review. Int J Mol Sci. 19:24102018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Long Y, Hang A, Zan GY, Shu XH, Wang YJ and Liu JG: The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and µ partial agonist, in mice. Psychopharmacology (Berl). 233:2411–2418. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kovalska M, Kovalska L, Tothova B, Mahmood S, Adamkov M and Lehotsky J: Combination of hyperhomocysteinemia and ischemic tolerance in experimental model of global ischemia in rats. J Physiol Pharmacol. 66:887–897. 2015.PubMed/NCBI | |
|
Dennis TS, Beck KD, Cominski TP, Bobzean SAM, Kuzhikandathil EV, Servatius RJ and Perrotti LI: Exposure to morphine-associated cues increases mu opioid receptor mRNA expression in the nucleus accumbens of Wistar Kyoto rats. Behav Brain Res. 313:208–213. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Menyhárt Á, Makra P, Szepes BE, Tóth OM, Hertelendy P, Bari F and Farkas E: High incidence of adverse cerebral blood flow responses to spreading depolarization in the aged ischemic rat brain. Neurobiol Aging. 36:3269–3277. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Xi C, Liang X, Ma J, Su D, Abel T and Liu R: The role of κ opioid receptor in brain ischemia. Crit Care Med. 44:e1219–e1225. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sobanski P, Krajnik M, Shaqura M, Bloch-Boguslawska E, Schäfer M and Mousa SA: The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels. 29:855–863. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jaiswal A, Kumar S, Seth S, Dinda AK and Maulik SK: Effect of U50,488H, a κ-opioid receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat. Mol Cell Biochem. 345:231–240. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamae I and Fukagawa M: Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis. 60:262–271. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang JL, Ren HW, He WF and Sun M: Butorphanol protects on myocardial ischemia/reperfusion injury in rats through MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 23:10541–10548. 2019.PubMed/NCBI | |
|
Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, et al: Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal. 9:ra1172016. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, He X, Yang Y, Chao D, Lazarus LH and Xia Y: Current research on opioid receptor function. Curr Drug Targets. 13:230–246. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI | |
|
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maneckjee R and Minna JD: Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA. 87:3294–3298. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Kuzumaki N, Suzuki A, Narita M, Hosoya T, Nagasawa A, Imai S, Yamamizu K, Morita H, Nagase H, Okada Y, et al: Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. Br J Cancer. 106:1148–1152. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sim EH, Yang IA, Wood-Baker R, Bowman RV and Fong KM: Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 1:CD0068472018.PubMed/NCBI | |
|
Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F and Ciardiello F: Erlotinib in cancer treatment. Ann Oncol. 18 (Suppl 6):vi35–vi41. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rho JK, Choi YJ, Ryoo BY, Na III, Yang SH, Kim CH and Lee JC: p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
An WF, Germain AR, Bishop JA, Nag PP, Metkar S, Ketterman J, Walk M, Weiwer M, Liu X, Patnaik D, et al: Discovery of potent and highly selective inhibitors of GSK3b. Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information (US); Bethesda (MD): 2010, PubMed/NCBI | |
|
Tian D, Zhu M, Chen WS, Li JS, Wu RL and Wang X: Role of glycogen synthase kinase 3 in squamous differentiation induced by cigarette smoke in porcine tracheobronchial epithelial cells. Food Chem Toxicol. 44:1590–1596. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng H, Saito H, Masuda S, Yang X and Takano Y: Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res. 27:3561–3569. 2007.PubMed/NCBI | |
|
Oren M: Decision making by p53: Life, death and cancer. Cell Death Differ. 10:431–442. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Brown J, Wang H and Feng X: The role of glycogen synthase kinase 3-β in immunity and cell cycle: Implications in esophageal cancer. Arch Immunol Ther Exp (Warsz). 62:131–144. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maneckjee R, Biswas R and Vonderhaar BK: Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. 50:2234–2238. 1990.PubMed/NCBI | |
|
Hatzoglou A, Bakogeorgou E and Castanas E: The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol. 296:199–207. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Montagna G, Gupta HV, Hannum M, Tan KS, Lee J, Scarpa JR, Plitas G, Irie T, McCormick PJ, Fischer GW, et al: Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth. 126:367–376. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Abnet CC, Arnold M and Wei WQ: Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zylla D, Gourley BL, Vang D, Jackson S, Boatman S, Lindgren B, Kuskowski MA, Le C, Gupta K and Gupta P: Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 119:4103–4110. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Harper P, Hald O, Lwaleed BA, Kyyaly A, Johnston D, Cooper AJ and Birch B: The impact of morphine treatment on bladder cancer cell proliferation and apoptosis: In vitro studies. Exp Oncol. 40:190–193. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moon TD: The effect of opiates upon prostatic carcinoma cell growth. Biochem Biophys Res Commun. 153:722–727. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin PM and Castanas E: Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol. 335:255–265. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kampa M, Loukas S, Tsapis A and Castanas E: Receptorphin: A conserved peptide derived from the sequence of the opioid receptor, with opioid displacement activity and potent antiproliferative actions in tumor cells. BMC Pharmacol. 1:92001. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita H, Shuman L, Warrick JI, Raman JD and Degraff DJ: Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. Am J Clin Exp Urol. 6:164–171. 2018.PubMed/NCBI | |
|
Lec PM, Lenis AT, Golla V, Brisbane W, Shuch, Garraway IP, Reiter RE and Chamie K: The role of opioids and their receptors in urological malignancy: A review. J Urol. 204:1150–1159. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bohn LM, Belcheva MM and Coscia CJ: Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells. J Neurochem. 70:1819–1825. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Remmers AE, Clark MJ, Mansour A, Akil H, Woods JH and Medzihradsky F: Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther. 288:827–833. 1999.PubMed/NCBI | |
|
Giakoumettis D, Kritis A and Foroglou N: C6 cell line: The gold standard in glioma research. Hippokratia. 22:105–112. 2018.PubMed/NCBI | |
|
Bohn LM, Belcheva MM and Coscia CJ: Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: Evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem. 74:564–573. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Bohn LM, Belcheva MM and Coscia CJ: Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells. J Neurochem. 74:574–581. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kampa M, Margioris AN, Hatzoglou A, Dermitzaki I, Denizot A, Henry JF, Oliver C, Gravanis A and Castanas E: Kappa1-opioid binding sites are the dominant opioid binding sites in surgical specimens of human pheochromocytomas and in a human pheochromocytoma (KAT45) cell line. Eur J Pharmacol. 364:255–262. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Venihaki M, Gravanis A and Margioris AN: Kappa opioids exert a strong antiproliferative effect on PC12 rat pheochromocytoma cells. Peptides. 17:413–419. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Takekoshi K, Ishii K, Kawakami Y, Isobe K and Nakai T: kappa-Opioid inhibits catecholamine biosynthesis in PC12 rat pheochromocytoma cell. FEBS Lett. 477:273–277. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chatzaki E, Margioris AN, Makrigiannakis A, Castanas E, Georgoulias V and Gravanis A: Kappa opioids and TGFbeta1 interact in human endometrial cells. Mol Hum Reprod. 6:602–609. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li WW, Zhao WJ, Yang Y and Yang YM: Effects of TGF-β1 on the expression of endometrial stromal cell-related protein and mRNA. Eur Rev Med Pharmacol Sci. 24:11475–11480. 2020.PubMed/NCBI | |
|
Chatzaki E, Kouimtzoglou E, Margioris AN and Gravanis A: Transforming growth factor beta1 exerts an autocrine regulatory effect on human endometrial stromal cell apoptosis, involving the FasL and Bcl-2 apoptotic pathways. Mol Hum Reprod. 9:91–95. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chamouard P, Klein A, Martin E, Adloff M and Angel F: Regulatory role of enteric kappa opioid receptors in human colonic motility. Life Sci. 53:1149–1156. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, O'Dorisio MS, O'Dorisio TM and Howe JR: Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis. 31:935–944. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Kang G, Wang T and Huang H: Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 16:687–702. 2018.PubMed/NCBI | |
|
Mody K, Baldeo C and Bekaii-Saab T: Antiangiogenic therapy in colorectal cancer. Cancer J. 24:165–170. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Husein B, Abdalla M, Trepte M, Deremer DL and Somanath PR: Antiangiogenic therapy for cancer: An update. Pharmacotherapy. 32:1095–1111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69 (Suppl 3):S4–S10. 2005. View Article : Google Scholar | |
|
Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A and Lorenc T: Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 21:58402020. View Article : Google Scholar : PubMed/NCBI | |
|
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S and Escudier B: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 32:752–759. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al: Neoadjuvant plus adjuvant bevacizumab in early breast cancer [NSABP B-40 (NRG Oncology)]: Secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 16:1037–1048. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamizu K, Furuta S, Hamada Y, Yamashita A, Kuzumaki N and Narita M, Doi K, Katayama S, Nagase H, Yamashita JK and Narita M: к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling. Sci Rep. 3:32132013. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamizu K and Yamashita JK: Roles of cyclic adenosine monophosphate signaling in endothelial cell differentiation and arterial-venous specification during vascular development. Circ J. 75:253–260. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr Med. 18:121–126. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C and Flavell RA: Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L and Chuang RY: Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun. 216:922–930. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kao TK, Ou YC, Liao SL, Chen WY, Wang CC, Chen SY, Chiang AN and Chen CJ: Opioids modulate post-ischemic progression in a rat model of stroke. Neurochem Int. 52:1256–1265. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Yang M, Chen C, Liu L, Wei X and Zeng S: Toll-Like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. Front Immunol. 11:14552020. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenstein TK: The role of opioid receptors in immune system function. Front Immunol. 10:29042019. View Article : Google Scholar : PubMed/NCBI | |
|
Finley MJ, Happel CM, Kaminsky DE and Rogers TJ: Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol. 252:146–154. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Multhoff G and Vaupel P: Hypoxia compromises anti-cancer immune responses. Adv Exp Med Biol. 1232:131–143. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dehne N, Mora J, Namgaladze D, Weigert A and Brüne B: Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol. 35:12–19. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xi C, Liang X, Chen C, Babazada H, Li T and Liu R: Hypoxia induces internalization of κ-opioid receptor. Anesthesiology. 126:842–854. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Babcock J, Herrera A, Coricor G, Karch C, Liu AH, Rivera-Gines A and Ko JL: Mechanism governing human kappa-opioid receptor expression under desferrioxamine-induced hypoxic mimic condition in neuronal NMB cells. Int J Mol Sci. 18:2112017. View Article : Google Scholar : PubMed/NCBI | |
|
Brownstein MJ: A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 90:5391–5393. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA and Grond S: Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 93:247–257. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zylla D, Steele G and Gupta P: A systematic review of the impact of pain on overall survival in patients with cancer. Support Care Cancer. 25:1687–1698. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Boland JW and Pockley AG: Influence of opioids on immune function in patients with cancer pain: From bench to bedside. Br J Pharmacol. 175:2726–2736. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Juneja R: Opioids and cancer recurrence. Curr Opin Support Palliat Care. 8:91–101. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Amaram-Davila J, Davis M and Reddy A: Opioids and cancer mortality. Curr Treat Options Oncol. 21:222020. View Article : Google Scholar : PubMed/NCBI | |
|
Fujiwara Y, Yamamoto H and Monden M: Molecular biology-based surgery for the future progress of cancer treatment. Nihon Geka Gakkai Zasshi. 103:278–283. 2002.(In Japanese). PubMed/NCBI | |
|
Hashizume M and Tsugawa K: Robotic surgery and cancer: The present state, problems and future vision. Jpn J Clin Oncol. 34:227–237. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Baskar R, Lee KA, Yeo R and Yeoh KW: Cancer and radiation therapy: Current advances and future directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YT, Tan YJ and Oon CE: Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 834:188–196. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cross D and Burmester JK: Gene therapy for cancer treatment: Past, present and future. Clin Med Res. 4:218–227. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen WK and Miao CH: The effect of anesthetic technique on survival in human cancers: A meta-analysis of retrospective and prospective studies. PLoS One. 8:e565402013. View Article : Google Scholar : PubMed/NCBI | |
|
Gach K, Wyrębska A, Fichna J and Janecka A: The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol. 384:221–230. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Forget P, Aguirre JA, Bencic I, Borgeat A, Cama A, Condron C, Eintrei C, Eroles P, Gupta A, Hales TG, et al: How anesthetic, analgesic and other non-surgical techniques during cancer surgery might affect postoperative oncologic outcomes: A summary of current state of evidence. Cancers (Basel). 11:5922019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Liu Y, Li N, Zhang J and Zhang X: Oxycodone regulates incision-induced activation of neurotrophic factors and receptors in an acute post-surgery pain rat model. J Pain Res. 11:2663–2674. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ji J, Lin W, Vrudhula A, Xi J, Yeliseev A, Grothusen JR, Bu W and Liu R: Molecular interaction between butorphanol and κ-opioid receptor. Anesth Analg. 131:935–942. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M, Jin L, Li R, Zhu S, Ji M and Li W: Comparison of oxycodone and morphine on the proliferation, apoptosis and expression of related molecules in the A549 human lung adenocarcinoma cell line. Exp Ther Med. 12:559–566. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Li D, Duan J, Xu H, Li L, Tan D and Yan H: The pro- and anti-cancer effects of oxycodone are associated with epithelial growth factor receptor level in cancer cells. Biosci Rep. 40:BSR201935242020. View Article : Google Scholar : PubMed/NCBI | |
|
Gery S, Yin D, Xie D, Black KL and Koeffler HP: TMEFF1 and brain tumors. Oncogene. 22:2723–2727. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nie X, Gao L, Zheng M, Wang C, Wang S, Li X, Qi Y, Zhu L, Liu J and Lin B: Overexpression of TMEFF1 in endometrial carcinoma and the mechanism underlying its promotion of malignant behavior in cancer cells. J Cancer. 12:5772–5788. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nie X, Liu C, Guo Q, Zheng MJ, Gao LL, Li X, Liu DW, Zhu LC, Liu JJ and Lin B: TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer. Cancer Manag Res. 11:839–855. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Li Y, Shen Y, Xu Y and Zhang C: Butorphanol inhibits the malignant biological behaviors of ovarian cancer cells via down-regulating the expression of TMEFF1. Onco Targets Ther. 13:10973–10981. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ramirez MF, Gorur A and Cata JP: Opioids and cancer prognosis: A summary of the clinical evidence. Neurosci Lett. 746:1356612021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YH, Sun JF, Tao YM, Chi ZQ and Liu JG: The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin. 31:1065–1070. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ramirez MF, Gorur A and Cata JP: The role of opioids in cancer progression. Int Anesthesiol Clin Spring. 58:57–63. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rodrigue D, Winkelmann J, Price M, Kalandranis E, Klempner L and Kapoor-Hintzen N: Opioid misuse: An organizational response while managing cancer-related pain. Clin J Oncol Nurs. 24:170–176. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidhammer H, Erli F, Guerrieri E and Spetea M: Development of diphenethylamines as selective kappa opioid receptor ligands and their pharmacological activities. Molecules. 25:50922020. View Article : Google Scholar : PubMed/NCBI |
